Former executive at Albumedix Ltd
- RHA (recombinant human albumin) vs HSA (human serum albumin) and BSA (bovine serum albumin) – value proposition and biomanufacturing applications including C> (cell and gene therapy) and vaccines
- Demand outlook for rHA, synergies with Sartorius’s (ETR: SRT) existing portfolio including CellGenix, and Albumedix's growth outlook under new ownership
- Potential rationale behind Sartorius’s agreement to acquire Albumedix vs competing rHA suppliers and deal terms
- Implications for Sartorius’s competitive positioning in C> and other advanced therapies vs bioprocessing incumbents including Danaher (NYSE: DHR) and Thermo Fisher (NYSE: TMO)
Gain access to Premium Content
Submit your details to access up to 5 Forum Transcripts or to request a complimentary one week trial.